Home / Home

Gastric Cancer Research

Gastric cancer advances include HER2-directed therapy, CLDN18.2-targeting, perioperative regimens, and biomarker-informed immunotherapy.

Our Gastric Cancer Analysis

  • July 13, 2026Journal of Clinical OncologyACT-GI, randomized phase II, NCT05772546

    Avatrombopag Meets Its Primary Endpoint in 70% vs 17% of Patients With Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers, in a Small Trial Stopped Early at Interim Analysis: The Phase II ACT-GI Trial

    ACT-GI was a multicenter, randomized, double-blind, placebo-controlled, investigator-initiated phase II trial at four US sites. Forty-seven adults receiving chemotherapy for gastrointestinal cancers with persistent chemotherapy-induced thrombocytopenia (platelet count ≤85 × 10⁹/L on day 1 of a scheduled cycle despite adequate recovery time) were assigned 1:1 to oral avatrombopag (n = 23) or placebo (n = 24). The primary endpoint, a composite of platelet recovery to ≥100 × 10⁹/L, completing one on-study chemotherapy cycle without thrombocytopenia-related dose reduction or delay, and ≥100 × 10⁹/L at the start of the next cycle, was met by 16 of 23 patients (70%; 95% CI, 47 to 87) with avatrombopag vs 4 of 24 (17%; 95% CI, 5 to 37) with placebo (Z = 3.67, P < .001).

  • September 24, 2026JAMA Oncology

    Modifiable Risk Factors Account for an Estimated 84% of the Male–Female Cancer Gap in China but 26% in the UK

    A multicohort analysis of 589,766 adults aged 40 to 74 years without prior cancer, drawn from the Shanghai Men’s Health Study, the Shanghai Women’s Health Study and UK Biobank, estimated how much of the higher cancer incidence in males is attributable to 11 lifestyle factors and health conditions.

  • September 24, 2026Nature MedicineASPEN-06 (NCT05002127)

    Evorpacept Combination Boosts Response Rate in HER2+ Gastric Cancer, but Misses Statistical Bar

    The phase 2 portion of ASPEN-06, a randomized, open-label trial, tested whether adding the CD47-blocking fusion protein evorpacept to trastuzumab, ramucirumab and paclitaxel (TRP) improves outcomes in previously treated, HER2-overexpressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

  • September 22, 2026Nature MedicinePATHFINDER 2 (NCT05155605)

    Multi-Cancer Blood Test Reaches 60% Positive Predictive Value and 99.6% Specificity in Largest Prospective Screening Study to Date

    PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.

  • August 20, 2026JAMA Oncology

    Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

    A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

Related topics: Fixed-Duration and De-escalated Therapy · HER2-Directed Therapy